cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.21227/w9xw-sd30
title: Devanagari Handwritten CAPTCHA - Dataset of 90 K Images : A Challenge Test

description: Captcha stands for Completely Automated Public Turing Tests to Distinguish Between Humans and Computers. This test cannot be successfully completed by current computer systems; only humans can. It is applied in several contexts for machine and human identification. The most common kind found on websites are text-based CAPTCHAs.A CAPTCHA is made up of a series of alphabets or numbers that are linked together in a certain order. Random lines, blocks, grids, rotations, and other sorts of noise have been used to distort this image.It is difficult for rural residents who only speak their local tongues to pass the test because the majority of the letters in this protected CAPTCHA script are in English. Machine identification of Devanagari characters is significantly more challenging due to their higher character complexity compared to normal English characters and numeral-based CAPTCHAs. The vast majority of official Indian websites exclusively provide content in Devanagari. Regretfully, websites do not employ CAPTCHAs in Devanagari. Because of this, we have developed a brand-new text-based CAPTCHA using Devanagari writing.A canvas was created using Python. This canvas code is distributed to more than one hundred (100+) Devanagari native speakers of all ages, including both left- and right-handed computer users. Each user writes 440 characters (44 characters multiplied by 10) on the canvas and saves it on their computers. All user data is then gathered and compiled. The character on the canvas is black with a white background. No noise in the image is a benefit of using canvas. The final data set contains a total of 44,000 digitized images, 10,000 numerals, 4000 vowels, and 30,000 consonants. This dataset was published for research scholars for recognition and other applications on Mendeley (Mendeley Data, DOI: 10.17632/yb9rmfjzc2.1, dated October 5, 2022) and the IEEE data port (DOI: 10.21227/9zpv-3194, dated October 6, 2022).We have designed our own algorithm to design the Handwritten Devanagari CAPTCHA. We used the above-created handwritten character set. General CAPTCHA generation principles are used to add noise to the image using digital image processing techniques. The size of each CAPTCHA image is 250 x 90 pixels. Three (03) types of character sets are used: handwritten alphabets, handwritten digits, and handwritten alphabets and digits combined. For 09 Classes X 10,000 images , a Devanagari CAPTCHA data set of 90,0000 images was created using Python. All images are stored in CSV format for easy use to researchers. To make the CAPTCHA image less recognized or not easily broken. Passing a test identifying Devanagari alphabets is difficult. It is beneficial to researchers who are investigating captcha recognition in this area. This dataset is helpful to researchers in designing OCR to recognize Devanagari CAPTCHA and break it. If you are able to successfully bypass the CAPTCHA, please acknowledge us by sending an email to sanjayepate@gmail.com.
DOI: 10.26179/ek16-xv34
title: voyage_202324VT2
DOI: 10.6084/m9.figshare.24057360.v1
title: phoD database

description: Phosphorus availability, phoD-harboring bacteriarichness, soilaggregate, phoD gene abundance, alkaline phosphatase,mowing, nitrogen addition
DOI: 10.5281/zenodo.10280249
title: Hot summer training and heat-related illness among firefighter
DOI: 10.5281/zenodo.10280250
title: Hot summer training and heat-related illness among firefighter
DOI: 10.6084/m9.figshare.24784612.v1
title: Additional file 2 of Seed protein biotyping in Amaranthus species: a tool for rapid identification of weedy amaranths of concern

description: Supplementary Material 2: Additional file 2 (.Xlsx) Protein biotyping database. Details of all accessions used.
DOI: 10.6084/m9.figshare.24784618
title: Additional file 4 of Seed protein biotyping in Amaranthus species: a tool for rapid identification of weedy amaranths of concern

description: Supplementary Material 4: Additional file 4. (.Xlsx) Blind sample testing for samples from AAFC in Table 1. For each sample, three seeds were tested, and for each seed three technical replicates were ran.
DOI: 10.6084/m9.figshare.24784618.v1
title: Additional file 4 of Seed protein biotyping in Amaranthus species: a tool for rapid identification of weedy amaranths of concern

description: Supplementary Material 4: Additional file 4. (.Xlsx) Blind sample testing for samples from AAFC in Table 1. For each sample, three seeds were tested, and for each seed three technical replicates were ran.
DOI: 10.6084/m9.figshare.24784612
title: Additional file 2 of Seed protein biotyping in Amaranthus species: a tool for rapid identification of weedy amaranths of concern

description: Supplementary Material 2: Additional file 2 (.Xlsx) Protein biotyping database. Details of all accessions used.
DOI: 10.6084/m9.figshare.24784621
title: Additional file 5 of Seed protein biotyping in Amaranthus species: a tool for rapid identification of weedy amaranths of concern

description: Supplementary Material 5: Additional file 5. (.Xlsx) Blind sample testing for samples from CFIA SSST in Table 2. Three technical replicates were run per seed.
DOI: 10.6084/m9.figshare.24784621.v1
title: Additional file 5 of Seed protein biotyping in Amaranthus species: a tool for rapid identification of weedy amaranths of concern

description: Supplementary Material 5: Additional file 5. (.Xlsx) Blind sample testing for samples from CFIA SSST in Table 2. Three technical replicates were run per seed.
DOI: 10.6084/m9.figshare.24784645
title: Additional file 1 of The epidemiology of primary FSGS including cluster analysis over a 20-year period

description: Additional file 1: Supplement material 1. Raw anonymised data file of the 87 patients included within the study.
DOI: 10.6084/m9.figshare.24784645.v1
title: Additional file 1 of The epidemiology of primary FSGS including cluster analysis over a 20-year period

description: Additional file 1: Supplement material 1. Raw anonymised data file of the 87 patients included within the study.
DOI: 10.6084/m9.figshare.24784485
title: D9-P5-DailyTemp-pH

description: The pH was recorded once daily along with the EC. The temperature was recorded every 10 seconds.
DOI: 10.6084/m9.figshare.24785142
title: Supplementary Material for: Abrocitinib Provides Rapid and Sustained Improvement in Skin Pain and Is Associated With Improved Quality of Life Outcomes in Adult and Adolescent Patients With Moderate-to-Severe Atopic Dermatitis

description: Background: Skin pain in atopic dermatitis (AD) increases with disease severity and is associated with substantial quality of life (QoL) burden. 
Objectives: To evaluate abrocitinib efficacy on skin pain and QoL in adults and adolescents with moderate-to-severe AD.
Methods: This post hoc analysis included data with abrocitinib administered as monotherapy (pooled phase 2b [NCT02780167] and phase 3 JADE MONO-1 [NCT03349060] and MONO-2 [NCT03575871]) or in combination with topical therapy (phase 3 JADE COMPARE [NCT03720470] and JADE TEEN [NCT03796676]). Patients received oral, once-daily abrocitinib 200 mg, abrocitinib 100 mg, or placebo for 12 or 16 weeks (JADE COMPARE). Skin pain was rated using the Pruritus and Symptoms Assessment for Atopic Dermatitis (PSAAD) skin pain Numerical Rating Scale (NRS) item (“How painful was your skin over the past 24 hours?”) on a scale from 0 (not painful) to 10 (extremely painful). Itch (Peak Pruritus NRS) and QoL (Dermatology Life Quality Index or Children’s Dermatology Life Quality Index) were assessed. Least squares mean (LSM) change from baseline was analyzed using mixed effects repeated measures modeling.
Results: A total of 1822 patients (monotherapy pool, n=942; JADE COMPARE, n=595; JADE TEEN; n=285) were analyzed. LSM change from baseline in PSAAD skin pain score was significantly greater with abrocitinib versus placebo from week 2 through week 12 or 16 across all 3 study populations and occurred in a dose-dependent manner. A greater proportion of patients achieved a ≥4-point improvement from baseline in PSAAD skin pain score with abrocitinib (200 mg and 100 mg) versus placebo in the monotherapy pool (56% and 38% vs 12%; week 12), JADE COMPARE (72% and 52% vs 26%; week 16), and JADE TEEN (51% and 60% vs 31%; week 12). Additionally, a greater proportion of patients achieved a stringent threshold of skin pain improvement (PSAAD skin pain score &lt;2) with abrocitinib versus placebo. Adults and adolescents who achieved a ≥4-point improvement in skin pain reported greater QoL improvement than those who did not achieve a ≥4-point improvement. A positive correlation (≥0.3) was observed between skin pain and QoL and separately between skin pain and itch across the 3 study populations.
Conclusion: Abrocitinib as monotherapy or in combination with topical therapy improved skin pain and was associated with improved QoL in both adults and adolescents with moderate-to-severe AD across all evaluated studies.
DOI: 10.6084/m9.figshare.24785145
title: Supplementary Material for: Abrocitinib Provides Rapid and Sustained Improvement in Skin Pain and Is Associated With Improved Quality of Life Outcomes in Adult and Adolescent Patients With Moderate-to-Severe Atopic Dermatitis

description: Background: Skin pain in atopic dermatitis (AD) increases with disease severity and is associated with substantial quality of life (QoL) burden. 
Objectives: To evaluate abrocitinib efficacy on skin pain and QoL in adults and adolescents with moderate-to-severe AD.
Methods: This post hoc analysis included data with abrocitinib administered as monotherapy (pooled phase 2b [NCT02780167] and phase 3 JADE MONO-1 [NCT03349060] and MONO-2 [NCT03575871]) or in combination with topical therapy (phase 3 JADE COMPARE [NCT03720470] and JADE TEEN [NCT03796676]). Patients received oral, once-daily abrocitinib 200 mg, abrocitinib 100 mg, or placebo for 12 or 16 weeks (JADE COMPARE). Skin pain was rated using the Pruritus and Symptoms Assessment for Atopic Dermatitis (PSAAD) skin pain Numerical Rating Scale (NRS) item (“How painful was your skin over the past 24 hours?”) on a scale from 0 (not painful) to 10 (extremely painful). Itch (Peak Pruritus NRS) and QoL (Dermatology Life Quality Index or Children’s Dermatology Life Quality Index) were assessed. Least squares mean (LSM) change from baseline was analyzed using mixed effects repeated measures modeling.
Results: A total of 1822 patients (monotherapy pool, n=942; JADE COMPARE, n=595; JADE TEEN; n=285) were analyzed. LSM change from baseline in PSAAD skin pain score was significantly greater with abrocitinib versus placebo from week 2 through week 12 or 16 across all 3 study populations and occurred in a dose-dependent manner. A greater proportion of patients achieved a ≥4-point improvement from baseline in PSAAD skin pain score with abrocitinib (200 mg and 100 mg) versus placebo in the monotherapy pool (56% and 38% vs 12%; week 12), JADE COMPARE (72% and 52% vs 26%; week 16), and JADE TEEN (51% and 60% vs 31%; week 12). Additionally, a greater proportion of patients achieved a stringent threshold of skin pain improvement (PSAAD skin pain score &lt;2) with abrocitinib versus placebo. Adults and adolescents who achieved a ≥4-point improvement in skin pain reported greater QoL improvement than those who did not achieve a ≥4-point improvement. A positive correlation (≥0.3) was observed between skin pain and QoL and separately between skin pain and itch across the 3 study populations.
Conclusion: Abrocitinib as monotherapy or in combination with topical therapy improved skin pain and was associated with improved QoL in both adults and adolescents with moderate-to-severe AD across all evaluated studies.
DOI: 10.6084/m9.figshare.24785145.v1
title: Supplementary Material for: Abrocitinib Provides Rapid and Sustained Improvement in Skin Pain and Is Associated With Improved Quality of Life Outcomes in Adult and Adolescent Patients With Moderate-to-Severe Atopic Dermatitis

description: Background: Skin pain in atopic dermatitis (AD) increases with disease severity and is associated with substantial quality of life (QoL) burden. 
Objectives: To evaluate abrocitinib efficacy on skin pain and QoL in adults and adolescents with moderate-to-severe AD.
Methods: This post hoc analysis included data with abrocitinib administered as monotherapy (pooled phase 2b [NCT02780167] and phase 3 JADE MONO-1 [NCT03349060] and MONO-2 [NCT03575871]) or in combination with topical therapy (phase 3 JADE COMPARE [NCT03720470] and JADE TEEN [NCT03796676]). Patients received oral, once-daily abrocitinib 200 mg, abrocitinib 100 mg, or placebo for 12 or 16 weeks (JADE COMPARE). Skin pain was rated using the Pruritus and Symptoms Assessment for Atopic Dermatitis (PSAAD) skin pain Numerical Rating Scale (NRS) item (“How painful was your skin over the past 24 hours?”) on a scale from 0 (not painful) to 10 (extremely painful). Itch (Peak Pruritus NRS) and QoL (Dermatology Life Quality Index or Children’s Dermatology Life Quality Index) were assessed. Least squares mean (LSM) change from baseline was analyzed using mixed effects repeated measures modeling.
Results: A total of 1822 patients (monotherapy pool, n=942; JADE COMPARE, n=595; JADE TEEN; n=285) were analyzed. LSM change from baseline in PSAAD skin pain score was significantly greater with abrocitinib versus placebo from week 2 through week 12 or 16 across all 3 study populations and occurred in a dose-dependent manner. A greater proportion of patients achieved a ≥4-point improvement from baseline in PSAAD skin pain score with abrocitinib (200 mg and 100 mg) versus placebo in the monotherapy pool (56% and 38% vs 12%; week 12), JADE COMPARE (72% and 52% vs 26%; week 16), and JADE TEEN (51% and 60% vs 31%; week 12). Additionally, a greater proportion of patients achieved a stringent threshold of skin pain improvement (PSAAD skin pain score &lt;2) with abrocitinib versus placebo. Adults and adolescents who achieved a ≥4-point improvement in skin pain reported greater QoL improvement than those who did not achieve a ≥4-point improvement. A positive correlation (≥0.3) was observed between skin pain and QoL and separately between skin pain and itch across the 3 study populations.
Conclusion: Abrocitinib as monotherapy or in combination with topical therapy improved skin pain and was associated with improved QoL in both adults and adolescents with moderate-to-severe AD across all evaluated studies.
DOI: 10.34740/kaggle/ds/4144004
title: 🎤 Spotify Hamilton Soundtrack Playlist
DOI: 10.25919/k2ra-p165
title: Instream barriers in the Murray- Darling Basin

description: This dataset was produced for the Murray Darling Basin Authority to update the Weir Information System dataset. Each point in the dataset represents a structure in the network. The approximate location of each point aligns with GeoFabric v3 Surface Network. 
It includes some attributes, such as, crest height, fishway availability, weir pool length (when available). For the main barriers on the main streams these values have been updated through literature, data reviews and web searches (where available). 

This datasets is aligned to GeoFabric v3 and and it is provided as a '.csv' file with lat/long in ESPG 4326.
New information to complete updating these attribute is welcome.
DOI: 10.6084/m9.figshare.24785172
title: Supplementary Material for: Twelve-months outcomes after metabolic and bariatric surgery among youths participating in a structured preparation and follow-up program – Results of the Youth with Extreme obesity Study (YES)

description: Introduction: While invasive and associated with risks, metabolic and bariatric surgery (MBS) can promote sustained weight loss and substantial health benefits in youths with extreme obesity.The path toward informed decision making for or against MBS is poorly characterized and postoperative follow-up to assess risks and benefits is inconsistent. In youths with extreme obesity we aimed to evaluate decision making toward MBS, as well as MBS outcomes and adherence with follow-up and recommendations in the setting of a structured pre- and post- MBS.
Methods: Participants were recruited in the setting of the multicenter “Youth with Extreme Obesity Study” (YES). YES is a cohort study in adolescents and young adults aged 14–24 years with obesity (BMI≥30.0 kg/m2) who were recruited at four medical centers and one job center in Germany between 2012 and 2018. Participants at two medical centers with BMI≥35kg/m2, aged 14-24 years, and interested in pursuing MBS were included in the subproject 3 “Safety and effectiveness of weight loss surgery in adolescents with severe obesity within a structured pre- and post-surgery treatment program – an observational study” that comprised a 2-months pre- and 12-months post-MBS program. 
Results: Twenty-eight of 169 youths (17%) with BMI≥35kg/m2 were interested in MBS. Twenty-six fulfilled published eligibility criteria for MBS and participated in the structured pre- MBS preparation program. Of these, 9 participants (2 female) decided against, and 17 (n=11 females) decided for MBS (sleeve gastrectomy). The 12-months follow-up rate was high (16/17 [94%]) and all participants achieved significant weight reduction (ΔBMI:-16.1±5.6 kg/m2). Eleven of 16 participants (69%) reported taking the prescribed dietary supplements in the first year after MBS, but only five of them (31%) did so daily. In contrast to the high 12-month retention rate, follow-up after completion of the structured program was low at 24-months (9/16 [56%]) and at 36-months (5/15 [36%]) respectively. 
Conclusion: Participants demonstrated active decision making for or against MBS and high adherence with the structured pre- and 12 months post- MBS program, but participation was low thereafter. These findings endorse the need for longer-term structured post-MBS programs to capture long-term outcomes and provide adequate care in this vulnerable group at the transition to adulthood.
DOI: 10.5281/zenodo.10023554
title: LATEst data
DOI: 10.5281/zenodo.10023603
title: LATEst: data
DOI: 10.5281/zenodo.10021370
title: LATEst: data
DOI: 10.5281/zenodo.10021371
title: LATEst data
DOI: 10.5281/zenodo.10348298
title: LATEst: Efficient computation of hazard ratios and identification of causal relationships using 'natural experiments' in medical informatics databases
DOI: 10.5281/zenodo.10348299
title: LATEst: Efficient computation of hazard ratios and identification of causal relationships using 'natural experiments' in medical informatics databases
DOI: 10.6084/m9.figshare.24785238
title: Supplementary Material for: Abrocitinib Provides Rapid and Sustained Improvement in Skin Pain and Is Associated With Improved Quality of Life Outcomes in Adult and Adolescent Patients With Moderate-to-Severe Atopic Dermatitis

description: Background: Skin pain in atopic dermatitis (AD) increases with disease severity and is associated with substantial quality of life (QoL) burden. 
Objectives: To evaluate abrocitinib efficacy on skin pain and QoL in adults and adolescents with moderate-to-severe AD.
Methods: This post hoc analysis included data with abrocitinib administered as monotherapy (pooled phase 2b [NCT02780167] and phase 3 JADE MONO-1 [NCT03349060] and MONO-2 [NCT03575871]) or in combination with topical therapy (phase 3 JADE COMPARE [NCT03720470] and JADE TEEN [NCT03796676]). Patients received oral, once-daily abrocitinib 200 mg, abrocitinib 100 mg, or placebo for 12 or 16 weeks (JADE COMPARE). Skin pain was rated using the Pruritus and Symptoms Assessment for Atopic Dermatitis (PSAAD) skin pain Numerical Rating Scale (NRS) item (“How painful was your skin over the past 24 hours?”) on a scale from 0 (not painful) to 10 (extremely painful). Itch (Peak Pruritus NRS) and QoL (Dermatology Life Quality Index or Children’s Dermatology Life Quality Index) were assessed. Least squares mean (LSM) change from baseline was analyzed using mixed effects repeated measures modeling.
Results: A total of 1822 patients (monotherapy pool, n=942; JADE COMPARE, n=595; JADE TEEN; n=285) were analyzed. LSM change from baseline in PSAAD skin pain score was significantly greater with abrocitinib versus placebo from week 2 through week 12 or 16 across all 3 study populations and occurred in a dose-dependent manner. A greater proportion of patients achieved a ≥4-point improvement from baseline in PSAAD skin pain score with abrocitinib (200 mg and 100 mg) versus placebo in the monotherapy pool (56% and 38% vs 12%; week 12), JADE COMPARE (72% and 52% vs 26%; week 16), and JADE TEEN (51% and 60% vs 31%; week 12). Additionally, a greater proportion of patients achieved a stringent threshold of skin pain improvement (PSAAD skin pain score &lt;2) with abrocitinib versus placebo. Adults and adolescents who achieved a ≥4-point improvement in skin pain reported greater QoL improvement than those who did not achieve a ≥4-point improvement. A positive correlation (≥0.3) was observed between skin pain and QoL and separately between skin pain and itch across the 3 study populations.
Conclusion: Abrocitinib as monotherapy or in combination with topical therapy improved skin pain and was associated with improved QoL in both adults and adolescents with moderate-to-severe AD across all evaluated studies.
DOI: 10.6084/m9.figshare.24785238.v1
title: Supplementary Material for: Abrocitinib Provides Rapid and Sustained Improvement in Skin Pain and Is Associated With Improved Quality of Life Outcomes in Adult and Adolescent Patients With Moderate-to-Severe Atopic Dermatitis

description: Background: Skin pain in atopic dermatitis (AD) increases with disease severity and is associated with substantial quality of life (QoL) burden. 
Objectives: To evaluate abrocitinib efficacy on skin pain and QoL in adults and adolescents with moderate-to-severe AD.
Methods: This post hoc analysis included data with abrocitinib administered as monotherapy (pooled phase 2b [NCT02780167] and phase 3 JADE MONO-1 [NCT03349060] and MONO-2 [NCT03575871]) or in combination with topical therapy (phase 3 JADE COMPARE [NCT03720470] and JADE TEEN [NCT03796676]). Patients received oral, once-daily abrocitinib 200 mg, abrocitinib 100 mg, or placebo for 12 or 16 weeks (JADE COMPARE). Skin pain was rated using the Pruritus and Symptoms Assessment for Atopic Dermatitis (PSAAD) skin pain Numerical Rating Scale (NRS) item (“How painful was your skin over the past 24 hours?”) on a scale from 0 (not painful) to 10 (extremely painful). Itch (Peak Pruritus NRS) and QoL (Dermatology Life Quality Index or Children’s Dermatology Life Quality Index) were assessed. Least squares mean (LSM) change from baseline was analyzed using mixed effects repeated measures modeling.
Results: A total of 1822 patients (monotherapy pool, n=942; JADE COMPARE, n=595; JADE TEEN; n=285) were analyzed. LSM change from baseline in PSAAD skin pain score was significantly greater with abrocitinib versus placebo from week 2 through week 12 or 16 across all 3 study populations and occurred in a dose-dependent manner. A greater proportion of patients achieved a ≥4-point improvement from baseline in PSAAD skin pain score with abrocitinib (200 mg and 100 mg) versus placebo in the monotherapy pool (56% and 38% vs 12%; week 12), JADE COMPARE (72% and 52% vs 26%; week 16), and JADE TEEN (51% and 60% vs 31%; week 12). Additionally, a greater proportion of patients achieved a stringent threshold of skin pain improvement (PSAAD skin pain score &lt;2) with abrocitinib versus placebo. Adults and adolescents who achieved a ≥4-point improvement in skin pain reported greater QoL improvement than those who did not achieve a ≥4-point improvement. A positive correlation (≥0.3) was observed between skin pain and QoL and separately between skin pain and itch across the 3 study populations.
Conclusion: Abrocitinib as monotherapy or in combination with topical therapy improved skin pain and was associated with improved QoL in both adults and adolescents with moderate-to-severe AD across all evaluated studies.